Abstract
Our study seeks to further characterize the impact of CLASI-A erythema and scale on patient quality of life in a larger multicentre cohort study. We found that both erythema and scale were associated with several PROMs, both at baseline and over time, most notably with patient impressions of disease progression. These findings justify the inclusion of erythema and scale in CLASI-A scoring and has important implications for future treatment directions, as no accepted measure of disease severity currently exists for cutaneous lupus erythematosus.